Clinical Trial

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Study acronym: TRIUMPH-5
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2026-12 -> 2026-11 2026-07-21
Trial Details
NCT Number NCT06662383
Lead Sponsor Eli Lilly and Company
Conditions Obesity
Enrollment 800 participants
Start Date 2024-11-01
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-20